Monthly Or Bust: Zalbin's Chances For Approval Likely Rest On Monthly Use Data
FDA indicates risk-to-benefit ratio is insufficient to approve Human Genome Sciences' next-generation interferon for biweekly dosing.
FDA indicates risk-to-benefit ratio is insufficient to approve Human Genome Sciences' next-generation interferon for biweekly dosing.